We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MOHAP Selects Masimo's (MASI) Eve for CCHD Screening in UAE
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) recently announced that the UAE Ministry of Health & Prevention (MOHAP) has adopted the company’s flagship Eve application. The device, which functions through Rad-97 Pulse CO-Oximeter, will be used for critical congenital heart disease (CCHD) screening in newborns. Notably, it will be installed in nine hospitals of UAE.
Eve simplifies the CCHD screening process by providing visual instructions and easy-to-interpret display of results, which is cost effective.
Per statistics released by Shaikh Khalifa Medical City, more than 500 newborns are diagnosed with congenital heart disease in the UAE every year. Nearly 70% of them require cardiac surgery.
Hence, Masimo’s latest development has been a timely and strategic one.
Market Prospects
Per MarketsandMarkets, the global newborn screening market was estimated at about $438.9 million in 2013. It is expected to reach $819.6 million by 2019, at a CAGR of 11%.
The benefits of newborn screening programs, legislations and mandates along with technological advancements are fueling growth.
Price Performance
Buoyed by such positive developments, Masimo’s shares have increased 16.4%, against the industry’s decline of 6.2% in the past six months.
Masimo’s Global Exposure
Masimo has a significant international presence.
In the last reported quarter, the company’s worldwide shipments of non-invasive technology rose 12% to 53,600 units from the prior-year quarter’s figure.
Moreover, Masimo secured a substantial contract for its flagship Rad-67 with blood transfusion centers in Valencia, Spain.
Abiomed has a projected long-term earnings growth rate of 27%. The stock flaunts a Zacks Rank #1.
Integer Holdings has a projected long-term earnings growth rate of 15%. The stock carries a Zacks Rank #2 (Buy).
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
MOHAP Selects Masimo's (MASI) Eve for CCHD Screening in UAE
Masimo Corporation (MASI - Free Report) recently announced that the UAE Ministry of Health & Prevention (MOHAP) has adopted the company’s flagship Eve application. The device, which functions through Rad-97 Pulse CO-Oximeter, will be used for critical congenital heart disease (CCHD) screening in newborns. Notably, it will be installed in nine hospitals of UAE.
The company recently received the CE marking of Eve. (Read More: Masimo's Eve Gets CE Mark, Bolsters CCHD Diagnosis)
Eve simplifies the CCHD screening process by providing visual instructions and easy-to-interpret display of results, which is cost effective.
Per statistics released by Shaikh Khalifa Medical City, more than 500 newborns are diagnosed with congenital heart disease in the UAE every year. Nearly 70% of them require cardiac surgery.
Hence, Masimo’s latest development has been a timely and strategic one.
Market Prospects
Per MarketsandMarkets, the global newborn screening market was estimated at about $438.9 million in 2013. It is expected to reach $819.6 million by 2019, at a CAGR of 11%.
The benefits of newborn screening programs, legislations and mandates along with technological advancements are fueling growth.
Price Performance
Buoyed by such positive developments, Masimo’s shares have increased 16.4%, against the industry’s decline of 6.2% in the past six months.
Masimo’s Global Exposure
Masimo has a significant international presence.
In the last reported quarter, the company’s worldwide shipments of non-invasive technology rose 12% to 53,600 units from the prior-year quarter’s figure.
Moreover, Masimo secured a substantial contract for its flagship Rad-67 with blood transfusion centers in Valencia, Spain.
In the recent past, the company’s technologies were adopted by NU Hospitals, a Bangalore-based nephrology care center in India. (Read More: Masimo Products to Boost India-Based NU Hospitals' Systems)
Zacks Ranks & Key Picks
Masimo currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are, Genomic Health , Abiomed and Integer Holdings Corporation (ITGR - Free Report) .
Genomic Health has an expected earnings growth rate of 187.5% for the current quarter. The stock sports a Zacks Rank #1 (Strong Buy). You can see see the complete list of today’s Zacks #1 Rank stocks here.
Abiomed has a projected long-term earnings growth rate of 27%. The stock flaunts a Zacks Rank #1.
Integer Holdings has a projected long-term earnings growth rate of 15%. The stock carries a Zacks Rank #2 (Buy).
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>